Exagen logo_440x386 (1).jpg
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
October 21, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 13, 2021 16:15 ET | Exagen Inc.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Reports Second Quarter 2021 Results
August 09, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2021. ...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Appoints Ana Hooker to Board of Directors
July 30, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference
July 29, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021
July 26, 2021 16:06 ET | Exagen Inc.
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after...
Logo.png
Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets
July 19, 2021 20:10 ET | DelveInsight Business Research LLP
Las Vegas, USA, July 19, 2021 (GLOBE NEWSWIRE) -- Lupus Nephritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Lupus Pipeline Comprising a Broad Spectrum of Molecular Targets ...
Exagen_Full_RGB_Yahoo_600x216.png
AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions
July 13, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Elects Frank Stokes to Board of Directors
June 18, 2021 08:29 ET | Exagen Inc.
SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company’s stockholders approved the election of...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
June 17, 2021 07:30 ET | Biogen Inc.
Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited...